Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Professeur Emmanuelle DERNIS

📍 Caen (14)HospitalierRPPS 10002589645
📊 Reconnaissance scientifique : 33/100📝 243 articles publiés📚 HAL (8)

✨ Profil synthétique

IA · 01/05/2026

Le Professeur Emmanuelle Dernis est un rhumatologue hospitalier à Caen, avec une production scientifique importante dans le domaine de la rhumatologie. Ses recherches portent principalement sur les maladies auto-immunes et inflammatoires, notamment la polyarthrite rhumatoïde, la spondylarthrite et le lupus érythémateux systémique. Avec un h-index de 33 et 235 publications, elle est une figure académique notable dans son domaine.

Expertises présumées

  • Rheumatoid Arthritis
  • Spondyloarthritis
  • Systemic Lupus Erythematosus
  • Psoriasis
  • Sjögren
  • Thérapies biothérapeutiques non-anti-TNF
  • csDMARDs
  • Inhibiteurs de JAK

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

33

h articles cités ≥ h fois chacun. Un h de 33 = 33 publications avec 33+ citations.

Citations

3 355

Publications

243

i10-index

65

Thématiques principales

  • Rheumatoid Arthritis Research and Therapies ×115
  • Spondyloarthritis Studies and Treatments ×88
  • Psoriasis: Treatment and Pathogenesis ×43
  • Systemic Lupus Erythematosus Research ×34
  • Autoimmune and Inflammatory Disorders Research ×29

Affiliations FR : Centre Hospitalier Universitaire de Caen Normandie · Université de Caen Normandie

Voir sur OpenAlex ↗🆔 ORCID 0000-0001-6113-166X

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

    Annals of the rheumatic diseases · 2021

    📚 93 citations🎯 RCR 7.65Top 4% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
  • 2
    Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial

    JAMA · 2022

    📚 81 citations🎯 RCR 7.51Top 4% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    ImportanceFew treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica.ObjectiveTo compare the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica.Design, Setting, and ParticipantsThis double-blind, parallel-group, placebo-controlled randomized clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from February 2017 to October 2019. Final follow-up occurred in November 2020. Inclusion criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the C-reactive protein level [CRP PMR-AS] >10) and prednisone dose greater than or equal to 10 mg per day.InterventionsPatients were randomly assigned to receive intravenous tocilizumab (8 mg/kg; n = 51) or placebo (n = 50) every 4 weeks for 24 weeks, combined with predefined standardized tapering of oral prednisone.Main Outcomes and MeasuresThe primary efficacy end point was CRP PMR-AS less than 10 (range, 0-100; higher values indicate greater activity; no minimal clinically important difference defined) combined with either prednisone dose less than or equal to 5 mg per day or a decrease in prednisone dose greater than or equal to 10 mg from baseline at week 24. There were 11 secondary outcomes assessed at week 24 included in this report, including disease activity (measured by CRP PMR-AS) and the proportion of patients no longer taking prednisone.ResultsOf the 101 randomized patients (mean age, 67.2 years; 68 [67.3%] women), 100 (99%) received at least 1 infusion and 100 completed the trial. The primary end point was achieved in 67.3% of patients in the tocilizumab group and 31.4% of patients in the placebo group (adjusted difference, 36.0% [95% CI, 19.4%-52.6%]; adjusted relative risk, 2.3 [95% CI, 1.5-3.6]; P < .001). Of 11 reported secondary end points at 24 weeks, 7 showed significant differences favoring tocilizumab, including mean CRP PMR-AS score (7.5 [95% CI, 5.4-9.6] vs 14.9 [95% CI, 11.4-18.4]; adjusted difference, −7.5 [95% CI, −11.2 to −3.8]; P < .001) and the percentage of patients no longer receiving prednisone (49.0% vs 19.6%; adjusted difference, 29.3% [95% CI, 18.9%-39.7%]; adjusted relative risk, 2.5 [95% CI, 1.8-3.5]; P < .001). The most frequent adverse events were infections, experienced by 23 patients (46.9%) in the tocilizumab group and 20 (39.2%) in the placebo group.Conclusions and RelevanceAmong patients with active polymyalgia rheumatica despite prednisone therapy, tocilizumab, compared with placebo, resulted in a significantly greater percentage of patients with a CRP PMR-AS less than 10 with reduced prednisone requirements at week 24. Further research is needed to confirm efficacy and to determine the balance of potential benefits and harms.Trial RegistrationClinicalTrials.gov Identifier: NCT02908217

  • 3
    Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

    The Lancet. Rheumatology · 2024

    📚 56 citations🎯 RCR 13.68Top 2% NIH🔓 Open Access

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal24

▼

Biothérapies non-anti-TNF5

▼

csDMARDs4

▼

Sjögren4

▼

Anti-TNF2

▼

Épidémiologie & registres2

▼

JAK inhibiteurs2

▼

Qualité de vie / PROMs2

▼

AINS1

▼

Anti-IL-171

▼

Essai clinique1

▼

IA en rhumatologie1

▼

Recommandations1

▼

Stratégie thérapeutique1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.